Cascadian Therapeutics Announces FDA Orphan Drug Designation Granted to Tucatinib for the Treatment of HER2+ Metastatic Colorectal Cancer
September 27, 2017 07:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA")...
Tucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 Congress
September 11, 2017 06:00 ET
|
Cascadian Therapeutics, Inc.
Results from Pooled Analysis Support the Potential Utility of Tucatinib for Patients with HER2+ Metastatic Breast Cancer with Brain Metastases Data from Nonclinical Models Support Evaluation of...
Cascadian Therapeutics Announces Poster Presentations on Tucatinib in Multiple Tumor Types at the European Society for Medical Oncology (ESMO) 2017 Congress
August 28, 2017 08:30 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Aug. 28, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced posters on tucatinib in multiple tumor types will...
Cascadian Therapeutics Reports Second Quarter 2017 Financial Results
August 08, 2017 16:01 ET
|
Cascadian Therapeutics, Inc.
First Patients Randomized in Western Europe and Australia in Ongoing Global HER2CLIMB Registrational Trial of Tucatinib Conference Call Scheduled for Today at 4:30 p.m. ET SEATTLE, Aug. 08, 2017 ...
Cascadian Therapeutics Announces Positive Regulatory Update for Tucatinib in Europe
July 11, 2017 08:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, July 11, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced the outcome of discussions with the European...
Cascadian Therapeutics’ Lead Candidate, Tucatinib, Receives Orphan Drug Designation from FDA for Treatment of Breast Cancer Patients with Brain Metastases
June 08, 2017 08:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, June 08, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that tucatinib, an investigational oral, small...
Cascadian Therapeutics Reports First Quarter 2017 Financial Results Conference Call Scheduled for Today at 8:30 a.m. ET
May 09, 2017 07:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, May 09, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today reported financial results for the first quarter ended March...
Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress
January 05, 2017 08:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced an overview of recent progress for its...
Cascadian Therapeutics Amends HER2CLIMB Phase 2 Trial of Tucatinib in Metastatic HER2-Positive Breast Cancer to Support Registration
December 07, 2016 07:00 ET
|
Cascadian Therapeutics, Inc.
Updated Data from Phase 1b Triplet Combination Trial at SABCS; Increased Median PFS to 7.8 Months and ORR to 61 Percent; Median Duration of Response (MDR) at 10 Months in Third-line Setting for...